3 results
To characterize the PK of eltrombopag at steady state after oral administration in pediatric patients with SAA.Secondary (key only, see protocol page 40-41 for all objectives): Safety and tolerability. Efficacy (overall response rate ORR).
Primary ObjectiveTo explore the pharmacodynamics effects of topically applied OMN ono Tape-stripped skin of healthy volunteerso Tape-stripped and IMQ-primed skin of healthy volunteerso Tape-stripped skin prior to IMQ applicationSecondary Objectives…
The pivotal Phase III NETTER-1 study showed that Lutathera with best supportive care (30mg octreotide long-acting) provided a significant increase in PFS to patients with progressive midgut carcinoid tumors (at enrollment) compared to patients…